Reply to Corona and Cattaneo
Clin Infect Dis
.
2017 Sep 1;65(5):870-871.
doi: 10.1093/cid/cix390.
Authors
Roger L Nation
1
,
Samira M Garonzik
2
,
Visanu Thamlikitkul
3
,
Evangelos J Giamarellos-Bourboulis
4
,
Alan Forrest
2
,
David L Paterson
5
,
Jian Li
1
,
Fernanda P Silveira
6
Affiliations
1
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.
2
School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York.
3
Division of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
4
Fourth Department of Internal Medicine, University of Athens Medical School, Greece.
5
University of Queensland Center for Clinical Research, Royal Brisbane and Women's Hospital, Australia.
6
Division of Infectious Diseases, University of Pittsburgh Medical Center, Pennsylvania.
PMID:
29017285
PMCID:
PMC5849108
DOI:
10.1093/cid/cix390
No abstract available
Publication types
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Colistin*
Critical Illness*
Humans
Substances
Colistin
Grants and funding
R01 AI070896/AI/NIAID NIH HHS/United States